top of page

NEWS: Patient Access of Prism for PTSD™ Grows Across the US

grain_2.png

RE-IMAGINE
MENTAL HEALTHCARE 

Transforming evidence-based innovation into accessible mental health treatment to help change lives.

arrow.png

GrayMatters Health is leading a transformation by empowering mental healthcare professionals with an evidence-based technology that augments standard-of-care therapies to help improve patient outcomes and patient lives. This innovation is based on the world’s first digital biomarker of brain activity associated with mental health disorders.

​

Prism for PTSD is the first self-neuromodulation device to receive FDA clearance as a prescribed adjunct treatment for post-traumatic stress disorder (PTSD). Prism uses the amygdala-based biomarker to help patients learn to regulate brain activity associated with PTSD symptoms,

PRISM EMPOWERS

FDA-CLEARED.

As adjunctive treatment of symptoms associated with PTSD, to be used under the direction of a healthcare professional.

SCIENCE-BASED‭.‬

Prism’s amygdala-based biomarker technology

has been extensively researched.

IT WORKS.

In clinical trials, 67% of patients overall showed clinically significant symptom improvement  three months after completing treatment.

FITS YOUR CLINIC.

Installation and training in the morning and treat patients that same afternoon. Can be operated by a non-MD.

IT IS SAFE.

Mild side effects, such as headache and fatigue  self-resolved post treatment. 

PATIENTS LIKE IT‭.‬

Prism does not re-expose patients to trauma and  studies have shown
10% attrition.

IMPACT ON PATIENTS

“I am encouraged that Prism, as an adjunctive therapy, will significantly benefit patients with PTSD and allow clinics to offer more options and better outcomes."

​

Professor Charlie Marmar, Principal Investigator at
NYU Langone

PRISM IN ACTION

SIGN UP FOR NEWSLETTER

bottom of page